



Australian Biomedical & Healthcare

A Wealth of Investment Opportunities

Sam Guthrie
Senior Trade Commissioner
Australian Trade & Investment Commission

Why Australia



- 1 **4th** largest economy in the Asia region and **13th** largest in the world
- 2 **26th year** of consecutive annual economic growth
- 3 GDP of more than **US\$1.3 trillion** (1.7% of global economy)
- 4 **AAA rating** by all three credit rating agencies
- 5 A **strategic base** for exporting services and technologies to **high-growth Asian markets**
- 6 A **growing population** of currently **23.7 million**
- 7 Average annual real 2.9% GDP growth over the next five years forecasted – the **highest among major advanced economies**

Australia's World-Firsts



Penicillin
for civilian
use



Cervical
cancer
vaccine



Successful
clinical IVF
pregnancy



Discovering
the link between
gas, ulcers and
Helicobacter pylori



Commercial
cochlear device



'Spray-on
skin' for
burns
victims




Influenza
treatment



Extended wear
contact lens

Australia's World-Firsts

Research excellence




6 universities in the top 100 **for clinical, pre-clinical and health research**, positioning Australia sixth behind US, UK, Netherlands, Canada and Germany.


- Highly skilled scientists and excellent universities
- Collaborative research culture
- Track record in pioneering and developing medical products, technologies and therapies
- Advanced medical research infrastructure

Well educated, diverse workforce

Australia's labour force is one of the most educated, multicultural and multilingual in the world.



More than 40% of Australian workers on average hold a tertiary qualification



30% of workforce born overseas



10% speak an Asian language at home

Australian government commitment



Australian Government invested **A\$10.1 billion** to support R&D in 2016-17

\$840 million funding for the National Health and Medical Research Council



Strong **intellectual property protection**

Strategy setting:

- National Digital Health Strategy (2018-2022)



- Australian Medical Research and Innovation Strategy 2016-2021

Generous **R&D tax incentive**



Ideal market for clinical research




Multinational companies

undertaking clinical research in collaboration with the Australian medical science and technology industry include:

-
- Amgen
 - AstraZeneca
 - Baxter
 - Eli Lilly
 - GlaxoSmithKline
 - Merck (MSD)
 - Novartis
 - Pfizer
 - Roche
 - Sanofi



Sophisticated pharmaceutical and healthcare system



Competitive healthcare system with strong demand for new drugs and modern medical treatments:

- One of Asia-Pacific's largest healthcare markets and in the world's top 20
- A study of the world's most efficient healthcare systems ranked Australia 6th
- In top 10 countries for life expectancy (82.8 years).



Globally integrated pharmaceutical industry provides collaboration opportunities:

- Most major global groups are manufacturing in Australia



Innovative biotechnology industry:

- Ranked 5th globally for biotechnology innovation in 2016





**“ AUSTRADE
CAN HELP
YOU!**

Free and confidential assistance

National coordination

Advice on Australian government programs and approval processes

Market intelligence and investment opportunities

Identification of suitable investment locations and partners, and also arrange site visit



Australian support in Hong Kong



CONTACT US

 www.austrade.gov.au

 +852 2588 5300

 hongkong@austrade.gov.au